Alexza Pharmaceuticals

Alexza Pharmaceuticals, located in Mountain View, CA, is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's products are based on the Staccato system, a hand-held inhaler designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner. ADASUVE is the first and only inhalation therapy for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. ADASUVE combines Alexza’s proprietary Staccato system with loxapine, an antipsychotic medicinal product. The Staccato system is a hand-held inhaler that delivers a drug aerosol to the deep lung that results in intravenous-like pharmacokinetics and rapid systemic effects. Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., is Alexza's commercial partner for ADASUVE in the United States. Grupo Ferrer Internacional SA is Alexza's commercial partner for ADASUVE in Europe, Latin America and the Commonwealth of Independent States countries. ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.
Company Growth (employees)
Type
Public
HQ
Mountain View, US
Size (employees)
27 (est)
Alexza Pharmaceuticals is headquartered in Mountain View, US

Key People at Alexza Pharmaceuticals

Thomas B. King

Thomas B. King

President & CEO
August J. Moretti

August J. Moretti

Senior Vice President and CFO
Leighton Read

Leighton Read

Director
Darl Moreland

Darl Moreland

Vice President, Quality

Alexza Pharmaceuticals Office Locations

Alexza Pharmaceuticals has office in Mountain View
Mountain View, US

Alexza Pharmaceuticals Metrics

Alexza Pharmaceuticals Financials

Alexza Pharmaceuticals's revenue is $5.6 m in FY, 2014 which is a 88.4% decrease from the previous period.
FY, 2013FY, 2014

Revenue

$47.8 m$5.6 m

Revenue growth, %

(88.4%)

Gross profit

$36.6 m($10.4 m)

Operating expense total

$34.9 m$27.1 m

EBIT

$1.8 m($37.5 m)

Net Income

($39.6 m)($36.7 m)

Operating cash flow

($409 k)($2.1 m)
We estimate that Alexza Pharmaceuticals's current employees are approximately 26% female and 74% male.

Alexza Pharmaceuticals News

Alexza Pharmaceuticals Company Life

You may also be interested in